

BIGFOOT BIOMEDICAL® ANNOUNCES COO ROLE AND EXECUTIVE PROMOTIONS AS PRODUCT LAUNCH NEARS

New structure readies company for anticipated launch of
Bigfoot Unity™ Diabetes Management Program.

Milpitas, CA, March 13, 2020 – Bigfoot Biomedical, Inc. announced today key promotions and new reporting structures as the company readies for regulatory submission and commercial launch of Bigfoot Unity™ Diabetes Management Program. Regulatory submission is anticipated in 2020 for its ground-breaking approach to diabetes management for people with Type 1 and Type 2 insulin-requiring diabetes. Bigfoot Unity is a real-time, dose-decision system utilizing proprietary smart pen caps and integrating Abbott's FreeStyle Libre platform.

"It's an exciting time as we move toward regulatory submission and clearance this year for the Bigfoot Unity product, and this new executive structure takes us into this new phase."

Jeffrey Brewer
CEO, Bigfoot Biomedical

"It's an exciting time as we move toward regulatory submission and clearance this year for the Bigfoot Unity product, and this new executive structure takes us into this new phase," said Jeffrey Brewer, chief executive officer of Bigfoot Biomedical. "We have an incredibly talented, experienced team, many with deep, personal connections to diabetes who are working very hard on completing product development and FDA submission. It's great to be able to reward that hard work and the progress we've made."

Ian Hanson, who has spearheaded development and production of Bigfoot Unity, has been promoted to chief operating officer (COO). He'll now oversee launch production as well as development of next generation Bigfoot Unity and Bigfoot Autonomy systems. Hanson has 20 years of experience in device development with expert proficiency in drug delivery systems, working at both Unilife and Medtronic. He has years of experience specific to the diabetes field, including development and commercialization of insulin delivery devices and diabetes management systems.

Kate Lee, who has been with Bigfoot for 4.5 years, has been promoted to senior vice president (SVP) of regulatory and quality affairs, where she will continue to lead Bigfoot's regulatory and quality activities and take on leadership of the human factors function. Lee spent the first part of her career in R&D, leading teams in the development of innovative devices, before focusing on regulatory affairs. She earned a master's degree in Smart Product Design from Stanford and a bachelor's degree in Mechanical Engineering from Harvard.

With the naming of a COO and the executive promotions, CEO Jeffrey Brewer will focus more on corporate financing, strategic partnership development, and the build out of Bigfoot's commercialization capabilities.



Bigfoot Biomedical executives, Ian Hanson (left) and Kate Lee (right).

About Bigfoot Biomedical, Inc.

Bigfoot Biomedical was founded by a team of people with a personal connection to type 1 diabetes and, with its Bigfoot Unity and Bigfoot Autonomy programs, seeks to change the paradigm of care for insulin-requiring diabetes by leveraging data, connectivity, automation, and machine learning to reduce the burden on people with insulin-requiring diabetes and maximize the leverage of health care providers. Learn more at bigfootbiomedical.com. Follow us on Twitter @BigfootBiomed and Facebook.

Media Contact:

Red Maxwell

press@bigfootbiomedical.com